Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma



Status:Recruiting
Conditions:Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:10/4/2018
Start Date:May 30, 2018
End Date:December 31, 2023
Contact:Traci Hayat, RN
Email:traci.hayat@louisville.edu
Phone:502-629-3383

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Chemotherapy and Irreversible Electroporation (IRE) in the Treatment of Advanced Pancreatic Adenocarcinoma

Compare the efficacy and tolerability of IRE in combination with either FOLFIRINOX or
gemcitabine in patients with locally advanced pancreatic cancer.

Phase II study in which all patients undergoing IRE for the treatment of locally advanced
pancreatic carcinoma will receive either FOLFIRINOX or gemcitabine as peri-ablation
treatment.

Inclusion Criteria:

- greater than or equal to 18 years of age

- diagnosed with stage III pancreatic cancer

- tumor is measurable

- GFR > mL/min/1.73m2

- willing and able to comply with protocol requirements

- AST/ALT >3 times upper limit of normal

- stable surgical post-operative course as defined by operative surgeon

Exclusion Criteria:

- participating in another clinical trial for the treatment of cancer at the time of
screening

- pregnant or currently breast feeding

- have a cardiac pacemaker or ICD implanted that cannot be deactivated during IRE
procedure

- have non-removable implants with metal parts within 1 cm of the target lesion

- had a myocardial infarction within 3 months prior to enrollment
We found this trial at
1
site
University of Louisville
500 S Preston St
Louisville, Kentucky
(502) 852-5555
Principal Investigator: Robert Martin, MD, PhD
Phone: 502-629-3383
University of Louisville The University of Louisville is a state supported research university located in...
?
mi
from
Louisville, KY
Click here to add this to my saved trials